OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 15K ADMA derivative securities | OQRO

Home
Insider trades
ADMA Biologics, Inc.
CEO exercised or converted 15K ADMA derivative securities

Insider trades

Insider trade

CEO exercised or converted 15K ADMA derivative securities

Traded Dec 15, 2025 · Filed Dec 17, 2025

ADMADMA Biologics, Inc.ADMA

15K
Shares · @ $5.40

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 15, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 17, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-045737

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Dec 17, 2025, 2:00 AM UTC

Added to OQRO

Oct 6, 2026, 9:54 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

ADMA BIOLOGICS, INC.

Issuer CIK

1368514

Ticker

ADMA

Reporting person

Adam S Grossman

Relationship

Director, Officer

Officer title

President and CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Dec 15, 2025

Transaction code

Shares / units

15,000

Price per share

$5.40

Acquired / disposed

Acquired (A)

Shares owned after

2,028,850

Ownership form

Direct

Amendment

Footnotes from the filing

Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Around the same time

Adam S Grossman (President and CEO) sold ~$297K of ADMA Biologics, Inc.

Scheduled in advanceFiled 10mo ago

Adam S Grossman (President and CEO) sold ~$119K of ADMA Biologics, Inc.

Scheduled in advanceFiled 10mo ago

Adam S GrossmanPresident and CEO

Filed 10mo ago

15KDerivative units

Traded Dec 15, 2025 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record